2023
Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Prachason T, Erzin G, Pries L, Brondino N, Politi P, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Escarti M, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Üçok A, Alptekin K, Saka M, Arango C, O'Donovan M, van Os J, Rutten B, Guloksuz S, investigators G. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. Psychiatry Research 2023, 323: 115184. PMID: 37015164, DOI: 10.1016/j.psychres.2023.115184.Peer-Reviewed Original ResearchConceptsBenton Facial Recognition TestDegraded Facial Affect Recognition TaskWechsler Adult Intelligence Scale-Third EditionSchizophrenia spectrum disordersSocial cognitionCognitive domainsFacial affect recognition taskAffect recognition taskFacial Recognition TestCognitive impairmentRecognition testSpectrum disorderRecognition taskCross-sectional sampleHealthy controlsCognitionPsychosis spectrumShort versionUnaffected siblingsNeurocognitionEUGEI studySchizophreniaPerceptionImpairmentSiblingsAssociations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls
Lin B, Vermeulen J, Bolhuis K, Chang X, Schirmbeck F, van Eijk K, investigators G, Alizadeh B, Bartels-Velthuis A, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Rutten B, Guloksuz S, Luykx J, van Os J, Simons C, van Winkel R, Guloksuz S, Blankers M, van den Brink W, de Haan L, Luykx J. Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research 2023, 323: 115143. PMID: 36948018, DOI: 10.1016/j.psychres.2023.115143.Peer-Reviewed Original ResearchConceptsHealthy controlsSmoking behaviorPsychotic symptomsSchizophrenia symptomsUnaffected siblingsProspective cohort studySix-year followMental health symptomsSymptom dimensionsCohort studyRisk factorsDepressive symptomsPsychotic disordersPatientsPositive symptomsHealth symptomsNegative symptomsSimilar effect sizesSymptomsLinear mixed-effects modelsMixed-effects modelsGenetic riskMean numberPolygenic scoresOverall sample
2022
The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.Peer-Reviewed Original ResearchConceptsHealthy controlsCannabis useDegraded Facial Affect Recognition TaskPresent cross-sectional studyCross-sectional studyHigh genetic riskProgression of schizophreniaRegular cannabis useCognitive disturbancesRegular cannabisPsychosis riskPatientsSchizophreniaFacial emotion recognition performanceGenetic riskCannabisCurrent cannabisEUGEI studyLongitudinal studyAgeSiblingsAssociationRiskOnsetEffect relationship
2021
Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Richards AL, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, O'Donovan M, Rutten B, Guloksuz S. Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2021, 113: 110440. PMID: 34536513, DOI: 10.1016/j.pnpbp.2021.110440.Peer-Reviewed Original ResearchConceptsDegraded Facial Affect Recognition TaskFacial emotion recognitionEmotion recognitionFacial affect recognition taskAffect recognition taskSocial cognition impairmentsFER deficitsIndividual emotionsPRS-SCZFER accuracyRecognition taskHealthy controlsSchizotypy-RevisedCognition impairmentIntermediate phenotypesPsychosis riskStructured interviewsEUGEI studySchizophreniaTotal scoreSiblingsGenetic riskDifferent patternsPsychosisEmotionsAssociation of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings
Noyan H, Erdağ E, Tüzün E, Yaylım İ, Küçükhüseyin Ö, Hakan M, Gülöksüz S, Rutten B, Saka M, Atbaşoğlu C, Alptekin K, van Os J, Üçok A. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings. Schizophrenia Research 2021, 229: 27-37. PMID: 33609988, DOI: 10.1016/j.schres.2021.01.014.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersIL-1β levelsKYNA levelsHigher serum IL-1β levelsSerum IL-1β levelsHigher KYNA levelsTrp-Kyn pathwayKynurenic acid levelsSimilar clinical featuresPathophysiology of schizophreniaManifestations of schizophreniaKYN levelsSerum interleukinClinical featuresInflammatory cytokinesIL-1βClinical dataKynurenine pathwayTRP levelsSpectrum disorderControl groupAdvanced stageLow TrpPathway dysregulationPatients
2019
Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study
van Os J, Pries L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine 2019, 50: 1884-1897. PMID: 31414981, DOI: 10.1017/s003329171900196x.Peer-Reviewed Original ResearchConceptsPsychotic disordersPolygenic riskSchizophrenia polygenic riskGene-environment interactionsGenetic riskRelatives of patientsFirst-degree relativesPsychosis phenotypeAverage genetic riskIntermediate phenotypesHealthy siblingsCognitive intermediate phenotypesControl groupAnalysis of associationAverage riskPatientsEstimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study
Pries L, Lage-Castellanos A, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altinyazar V, Yalinçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Alizadeh B, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Luykx J, van Winkel R, Rutten B, van Os J, Arango C, O’Donovan M, Rutten B, van Os J, Guloksuz S. Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. Schizophrenia Bulletin 2019, 45: 960-965. PMID: 31508804, PMCID: PMC6737483, DOI: 10.1093/schbul/sbz054.Peer-Reviewed Original ResearchPsychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls
Çevik B, Mançe-Çalışır Ö, Atbaşoğlu E, Saka M, Alptekin K, Üçok A, Sırmatel B, Gülöksüz S, Tükün A, van Os J, Gümüş-Akay G. Psychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls. Journal Of Psychiatric Research 2019, 111: 169-185. PMID: 30776705, DOI: 10.1016/j.jpsychires.2019.01.022.Peer-Reviewed Original ResearchConceptsShorter telomere lengthLonger telomere lengthChildhood adversityTelomere lengthUnaffected siblingsSCZ patientsChronic medical disordersCourse of schizophreniaSimilar telomere lengthPsychotic-like symptomsHypothesis patientsClinical presentationNon-clinical controlsMedical disordersGeneral populationFunctioning scoresPatientsSchizophrenia patientsSocio-demographic featuresGlobal assessmentEarly onsetSchizophreniaLife expectancyAges 0Potential role
2018
Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia
Atbasoglu E, Gumus-Akay G, Guloksuz S, Saka M, Ucok A, Alptekin K, Gullu S, van Os J. Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia. Psychopharmacology 2018, 235: 1029-1039. PMID: 29306964, DOI: 10.1007/s00213-017-4818-z.Peer-Reviewed Original ResearchConceptsInsulin resistanceDopaminergic activityMetabolic profileHomeostatic model assessmentHDL-C levelsBetter metabolic profilesFavorable metabolic profilePancreatic insulin secretionUnaffected siblingsBeads taskResultsInsulin resistanceTertile groupRegression modelsCentral actionInsulin secretionGeneral populationGenetic predispositionGlucose metabolismModel assessmentSZ patientsRegulatory roleDirect actionSignificant predictorsHigher likelihoodLongitudinal study
2017
Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience
van Os J, van der Steen Y, Islam M, Gülöksüz S, Rutten B, Simons C. Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. Psychological Medicine 2017, 47: 2421-2437. PMID: 28436345, DOI: 10.1017/s0033291717000915.Peer-Reviewed Original ResearchConceptsPolygenic risk scoresHealthy comparison subjectsPsychotic disordersAttribution of salienceAffective episodesComparison subjectsIntelligence quotientTotal scorePolygenic riskFirst-degree relativesElevated genetic riskLower intelligence quotientManic episodesHealthy relativesRisk scoreNeurodevelopmental alterationsDepression subscaleLifetime ratesSimilar associationPsychosis riskFloor effectsGenetic riskPositive subscalePsychosis phenotypeDisorders